Ibrexafungerp, a Novel Triterpenoid Antifungal in Development for the Treatment of Mold Infections

Molds are ubiquitous in the environment, and immunocompromised patients are at substantial risk of morbidity and mortality due to their underlying disease and the resistance of pathogenic molds to currently recommended antifungal therapies. This combination of weakened-host defense, with limited ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Angulo, David A., Alexander, Barbara, Rautemaa-Richardson, Riina, Alastruey-Izquierdo, Ana, Hoenigl, Martin, Ibrahim, Ashraf S., Ghannoum, Mahmoud A., King, Thomas R., Azie, Nkechi E., Walsh, Thomas J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695964/
https://www.ncbi.nlm.nih.gov/pubmed/36354888
http://dx.doi.org/10.3390/jof8111121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695964/
https://www.ncbi.nlm.nih.gov/pubmed/36354888
http://dx.doi.org/10.3390/jof8111121

Ejemplares similares